A Study Analyzing Real-World Utilization and Factors Associated with the Use of Alternative Pembrolizumab Dosing Regimens-US-Based EMR Study
Latest Information Update: 22 Jun 2022
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 22 Jun 2022 New trial record
- 18 May 2022 Results presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research